We are proud to announce the close of our Series B financing, with participation from Vensana Capital, ShangBay Capital, and two multinational strategics. This milestone will accelerate our development of the next-generation AI-powered IVUS platform and support our path to FDA clearance and U.S. launch. At Evident Vascular, we are dedicated to improving life for patients suffering from vascular disease through innovative imaging solutions.
About us
Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.
- Website
-
https://evidentvascular.com
External link for Evident Vascular, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- San Jose, California
- Type
- Privately Held
- Founded
- 2021
- Specialties
- imaging, IVUS, intravascular, peripheral vascular, cardiovascular, PVD, CVD, PCI, image guided therapy , vascular, medtech, medtech startup, endovascular, interventional radiology , vascular surgery, and interventional cardiology
Locations
-
Primary
Get directions
142 Charcot Ave
San Jose, California 95131, US
Employees at Evident Vascular, Inc.
Updates
-
IVUS is a powerful tool that provides critical insights into vascular care, but despite its benefits, it remains underutilized. Watch as Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM, and S. Jay Mathews, MD, MS, FACC, FSCAI share their perspectives on the current state of IVUS, the barriers to broader adoption, and what’s needed to ensure more patients benefit from better imaging and informed decision-making. The value of IVUS is clear. Advancing its use will help improve outcomes for more patients. #IVUS #VascularImaging #PatientOutcomes
-
Breaking News: New ACC/AHA Guidelines! The newly updated American College of Cardiology / American Heart Association ACS guidelines emphasize the critical role of IVUS in interventional cardiology, reinforcing its value in complex PCI and high-risk patients. With clear recommendations supporting intravascular imaging, these guidelines mark an important milestone in evidence-based, image-guided interventions. As intravascular imaging becomes essential for better patient outcomes, this update highlights the need for broader IVUS integration into clinical practice. https://lnkd.in/emzKxguW #IVUS #ACS #AHA #Guidelines
-
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM highlights the game-changing impact of IVUS in vascular care--removing guesswork, improving precision, and keeping the focus on what matters most: the patient and their outcomes. Dive into how IVUS delivers better results for both clinicians and patients. #IVUS
IVUS is “not a free walk” – it is about the patient and the outcome, and takes out “the guesswork In conversation with Vascular News about IVUS, Eric A. Secemsky, (Beth Israel Deaconess Medical Center, Boston, USA, and a newly appointed editor of Vascular News North America) drilled down on the benefits of this technology in the vascular field. Paris Vascular Insights Course #PVI2024 #IVUS https://lnkd.in/eRdW4Pfz
-
We are proud to announce the addition of Scott Ward to our Board of Directors. Scott is a distinguished healthcare and medical technology leader, bringing decades of experience and a strategic perspective that will help guide Evident as we continue to grow and innovate. His expertise will be invaluable as we navigate this transformative time in our company’s growth and prepare for the exciting milestones ahead. His commitment to improving patient outcomes makes him a perfect fit for our mission. As we advance our next-generation AI-powered IVUS platform, his insights will be instrumental in shaping the future of vascular imaging and intervention. Welcome, Scott, to the Evident Vascular team!
-
Evident Vascular, Inc. reposted this
📢 ACC 2024 🗞️ Large prospective RCT demonstrates IVUS-guided DCB intervention in fempop 🦵 disease provides significantly improved clinical outcomes! Now if only there was a next generation IVUS platform with better image quality, improved ease of use, and AI-enabled capabilities that clinicians actually wanted to use… Check out —> Evident Vascular, Inc. Cc: Howard Rosen
Director of Vascular Intervention, BIDMC; Section Head, Interventional Cardiology and Vascular Research, Smith Center for Outcomes Research; Associate Professor of Medicine, Harvard Medical School
Second Prospective Randomized Control Trial Demonstrating the Benefit of Peripheral IVUS! 237 patients with fempop disease randomized to IVUS-guided DCB treatment vs angio-guided DCB treatment. 14% improvement in patency at 1 year. Summary of results here: https://lnkd.in/gU-3Vggz This aligns with the 17% patency improvement seen in the Allan et al 150 person fem-pop RCT trail published in 2022: (https://lnkd.in/gRtz-rQr). Time is now to change your peripheral practice!! Learn more about peripheral IVUS here: https://lnkd.in/g-m7EpWg Society for Vascular Medicine Society for Cardiovascular Angiography & Interventions Society of Interventional Radiology VIVA Physicians